Inclusion Criteria:  All patients treated with aflibercept in combination with FOLFIRI for mCRC after failure of an oxaliplatin-containing regimen (including patients pretreated with bevacizumab or anti-EGFR and patients treated with oxaliplatin in the adjuvant setting). Exclusively or predominantly hepatic metastases (≤ 5 pulmonary nodules < 2 cm). Age > 18 years. Signed consent for collection of personal and medical data. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.  Exclusion Criteria:  Concomitant participation in a clinical trial. Patient receiving concomitant anti-VEGF agents and/or receiving aflibercept as part of a clinical trial or in a compassionate use program. Patient receiving aflibercept in combination with chemotherapy other than FOLFIRI. Patient with contra-indication to surgery.  The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.